argenx SE opened a tender offer for Forte Biosciences this morning, no dollar figure disclosed. The Amsterdam-based immunology company is buying pipeline, not revenue—Forte operates in the dermatology-immunology intersection, a category where asset scarcity has pushed valuations into the upper decile of Phase II multiples since early 2024. argenx has $4.2 billion in trailing cash from VYVGART sales and European cardiovascular approvals, which creates room for bolt-on bets.
Forte's flagship candidate, FB-102, is a topical gel targeting atopic dermatitis, in mid-stage trials. The asset uses a Janus kinase inhibitor mechanism that overlaps with argenx's existing FcRn platform science, but sits outside intravenous infusion models. The tender structure—no cash multiple announced—signals either negotiation friction or a strategic preference to keep valuation optics quiet until closure. Tender timelines typically run 20 to 25 business days under SEC rules, which places the close window in mid-to-late May.
The move matters because argenx is building a second revenue pillar. VYVGART hit $1.8 billion in 2024 sales, ahead of Street consensus, but remains a single-product house. Dermatology assets offer oral and topical adjacencies that reduce administration burden and open access to earlier-line prescribing. Forte's pipeline also includes FB-401, a monoclonal antibody for chronic spontaneous urticaria, which sits in preclinical work but aligns with argenx's autoantibody expertise. The broader theme is portfolio durability—single-asset biotech valuations compressed 28 percent on average in Q1 2025 after three Phase III readouts missed endpoints, and argenx is preempting that risk.
Operators should track two follow-on events. First, the Hart-Scott-Rodino antitrust filing will surface within 15 days if the deal exceeds $126 million in value, which is the 2025 threshold for reportable transactions. Second, argenx's next earnings call on May 8 will clarify whether Forte's pipeline advances into pivotal trials or remains a mid-stage hedge. If argenx accelerates FB-102 into Phase III by year-end, the deal retroactively prices as a platform acquisition rather than an opportunistic tuck-in.
European biotech has completed nine dermatology-focused acquisitions since January, three of them at undisclosed valuations, which suggests competitive tension for topical immunology assets is high but not yet reflected in public comps.